Kinesys Oncology: ESMO Congress, Copenhagen, 7-11 October 2016

Update on Lung Cancers, plus selected highlights in other tumours 

Lung Cancer: http://emarketing.atalanta.uk.com/t/y-F1A2BEE45251C66C

RCC, Prostate, SCLC, Gastro-Oesophageal Cancers: http://emarketing.atalanta.uk.com/t/y-0F73DC93CC39BBDA

NSCLC

AstraZeneca: Selumetinib misses primary endpoint. Durvalumab: 80%, 6-month survival in Phase I / II study.

Merck’s Keytruda: Highly encouraging results in 1^st and 2^nd line treatment of squamous and non-squamous NSCLC.

BMS’ Opdivo: Disappointing update on 1^st line treatment of NSCLC. Better results in bladder, kidney and head & neck cancer.

Roche: Positive results in 2^nd / 3^rd line NSCLC – PD-L1 vs non-PD-L1.

Renal Cell Carcinoma

Exelixis / Ipsen: Significant improvement in Phase II Metastatic RCC (renal cell carcinoma) trial vs sunitinib.

Prostate Cancer

OncoGenex: Disappointing results in Phase III prostate cancer for custirsen.

SCLC

Takeda: Alisertib prolongs PFS in 2^nd line SCLC trial.

Gastric cancer

Ganymed: IMAB362 produced significant improvements in OS, PFS and ORR in gastric / gastro-oesophageal cancer patients.